0000318306
false
0000318306
2023-08-08
2023-08-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): August 8, 2023
ABEONA
THERAPEUTICS INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-15771 |
|
83-0221517 |
(State or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
6555
Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address
of principal executive offices) (Zip Code)
(646)
813-4701
(Registrant’s telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
ABEO |
|
Nasdaq
Capital Markets |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. |
Results of Operations
and Financial Condition. |
On
August 8, 2023, Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the second
quarter of 2023. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The
information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 | Financial
Statements and Exhibits. |
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Abeona Therapeutics Inc. |
|
(Registrant) |
|
|
|
|
By: |
/s/
Joseph Vazzano |
|
Name: |
Joseph Vazzano |
|
Title: |
Chief Financial Officer |
Date:
August 8, 2023
Exhibit
99.1
Abeona
Therapeutics Reports Second Quarter 2023 Financial Results
On
track for Biologics License Application (BLA) submission in third quarter of 2023
Proceeds
from $25 million registered direct offering in July allow initiation of pre-commercial launch activities for EB-101
Cash
on hand plus proceeds from registered direct offering projected to fund operations into the fourth quarter of 2024
CLEVELAND,
August 8, 2023 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2023 and provided
an update on progress toward achieving key corporate objectives.
“Abeona
is at a pivotal moment in our history as we are busy finalizing and planning to soon submit the BLA for EB-101 for the treatment of recessive
dystrophic epidermolysis bullosa,” said Vish Seshadri, Chief Executive Officer of Abeona. “The recent capital raise allows
us to initiate preparations for the commercial launch of EB-101 in the U.S., while also extending our cash runway well beyond the anticipated
regulatory approval time for EB-101.”
Second
Quarter and Recent Progress
Strengthened
balance sheet, preparing for commercialization of EB-101 in the U.S.
● | In
July, Abeona raised $25 million in a registered direct offering priced at-the-market with
select existing investors to primarily fund initiation of the Company’s launch preparations
in anticipation of the EB-101 BLA submission and potential approval. |
EB-101
for recessive dystrophic epidermolysis bullosa (RDEB)
● | Completed
the Process Performance Qualification manufacturing runs for both retroviral vector (RVV)
and EB-101 drug product manufacturing to demonstrate Abeona’s validated process and
readiness for commercial production. This data will be included in the chemistry, manufacturing,
and control (CMC) module for the EB-101 BLA submission. |
● | Generated
the additional data requested by the U.S. Food and Drug Administration (FDA) that supports
comparability between two RVV sources used in EB-101 clinical studies. This data will be
included in the CMC module for the EB-101 BLA submission. |
● | Abeona
submitted the briefing package for the pre-BLA meeting with the FDA in August 2023 for its
anticipated BLA submission of EB-101 in the treatment of RDEB. Abeona anticipates submitting
the BLA in the third quarter of 2023. |
● | Additional
efficacy and safety data from the pivotal Phase 3 VIITAL study of investigational EB-101
in RDEB were presented at the International Societies for Investigative Dermatology (ISID)
and Society for Pediatric Dermatology (SPD) meetings. The positive top-line data from the
VIITAL study were reported in November 2022. |
Preclinical
programs
● | Completed
pre-Investigational New Drug Application (IND) meetings with the FDA regarding the preclinical
development plans and regulatory requirements to support first-in-human trials for two preclinical
gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program.
The Company intends to initiate
IND-enabling studies in the second half of 2023. |
● | Abeona
presented new preclinical data at the 26th Annual Meeting of the American Society
of Gene & Cell Therapy (ASGCT), including data on three internally developed preclinical
gene therapy product candidates from its AAV ophthalmology program. |
Second
Quarter Financial Results
Cash,
cash equivalents, restricted cash and short-term investments totaled $37.1 million as of June 30, 2023, prior to the $25 million registered
direct offering in July 2023, as compared to $40.7 million as of March 31, 2023. Abeona estimates that its cash and cash equivalents,
restricted cash and short-term investments as of June 30, 2023, in addition to the proceeds from the $25 million registered direct offering
in July 2023, are sufficient resources to fund operations into the fourth quarter of 2024.
License
and other revenues in the second quarter of 2023 were $3.5 million, compared to $1.0 million in the second quarter of 2022. Research
and development expenses for the three months ended June 30, 2023 were $8.5 million, compared to $6.7 million for the same period of
2022. General and administrative expenses were $5.0 million for the three months ended June 30, 2023, compared to $3.5 million for the
same period of 2022. Net loss attributable to common shareholders was $16.7 million for the second quarter of 2023, or $0.92 loss per
common share as compared to a net loss attributable to common shareholders of $7.9 million, or $1.36 loss per common share, in the second
quarter of 2022.
Conference
Call Details
Abeona
Therapeutics will host a conference call and webcast today, August 8, 2023, at 8:30 a.m. ET, to discuss its financial results and business
update. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 446072 five minutes prior
to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section
of Abeona’s website at www.abeonatherapeutics.com. The archived webcast replay will be available for 30 days following the
call.
About
Abeona Therapeutics
Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s
lead clinical program is EB-101, its investigational autologous, engineered cell therapy currently in development for recessive dystrophic
epidermolysis bullosa. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with
high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety
of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produced EB-101 for the pivotal
Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information,
visit www.abeonatherapeutics.com.
Forward-Looking
Statements
This press release contains
certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking
statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,”
“intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances),
which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited
to, the timing and outcome of our Biologics License Application submission to the FDA for EB-101; continued interest in our rare disease
portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies,
including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any
changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed
in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange
Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances
occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required
by the federal securities laws.
Investor
and Media Contact:
Greg
Gin
VP,
Investor Relations and Corporate Communications
Abeona
Therapeutics
ir@abeonatherapeutics.com
ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES
Condensed
Consolidated Statements of Operations and Comprehensive Loss
(In
thousands, except share and per share amounts)
(Unaudited)
| |
For
the three months ended
June 30, | | |
For
the six months ended
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Revenues: | |
| | | |
| | | |
| | | |
| | |
License and other revenues | |
$ | 3,500 | | |
$ | 1,000 | | |
$ | 3,500 | | |
$ | 1,346 | |
| |
| | | |
| | | |
| | | |
| | |
Expenses: | |
| | | |
| | | |
| | | |
| | |
Royalties | |
| 1,575 | | |
| 350 | | |
| 1,575 | | |
| 350 | |
Research and development | |
| 8,523 | | |
| 6,658 | | |
| 16,564 | | |
| 17,203 | |
General and administrative | |
| 5,021 | | |
| 3,460 | | |
| 9,018 | | |
| 7,684 | |
Impairment of licensed technology | |
| — | | |
| — | | |
| — | | |
| 1,355 | |
Loss/(gain) on right-of-use lease assets | |
| (1,065 | ) | |
| — | | |
| (1,065 | ) | |
| 1,561 | |
Impairment of construction-in-progress | |
| — | | |
| (1,460 | ) | |
| — | | |
| 1,792 | |
Total expenses | |
| 14,054 | | |
| 9,008 | | |
| 26,092 | | |
| 29,945 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (10,554 | ) | |
| (8,008 | ) | |
| (22,592 | ) | |
| (28,599 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 417 | | |
| 31 | | |
| 781 | | |
| 38 | |
Interest expense | |
| (103 | ) | |
| (200 | ) | |
| (204 | ) | |
| (401 | ) |
Change in fair value of warrant liabilities | |
| (8,629 | ) | |
| 4,198 | | |
| (6,364 | ) | |
| 2,945 | |
Other income (expense) | |
| 2,215 | | |
| (118 | ) | |
| 2,618 | | |
| (124 | ) |
Net loss | |
$ | (16,654 | ) | |
$ | (4,097 | ) | |
$ | (25,761 | ) | |
$ | (26,141 | ) |
Deemed dividends related to Series A and Series B Convertible Redeemable Preferred Stock | |
| — | | |
| (3,782 | ) | |
| — | | |
| (3,782 | ) |
Net loss attributable to Common Shareholders | |
$ | (16,654 | ) | |
$ | (7,879 | ) | |
$ | (25,761 | ) | |
$ | (29,923 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per common share | |
$ | (0.92 | ) | |
$ | (1.36 | ) | |
$ | (1.48 | ) | |
$ | (5.16 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of common | |
| | | |
| | | |
| | | |
| | |
shares outstanding – basic and diluted | |
| 18,017,874 | | |
| 5,806,473 | | |
| 17,464,026 | | |
| 5,800,822 | |
| |
| | | |
| | | |
| | | |
| | |
Other comprehensive income (loss): | |
| | | |
| | | |
| | | |
| | |
Change in unrealized gains (losses) related to available-for-sale debt securities | |
| (30 | ) | |
| (4 | ) | |
| 34 | | |
| (7 | ) |
Comprehensive loss | |
$ | (16,684 | ) | |
$ | (7,883 | ) | |
$ | (25,727 | ) | |
$ | (29,930 | ) |
ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES
Condensed
Consolidated Balance Sheets
(In
thousands, except share and per share amounts)
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 6,225 | | |
$ | 14,217 | |
Short-term investments | |
| 30,547 | | |
| 37,932 | |
Restricted cash | |
| 338 | | |
| 338 | |
Accounts receivable | |
| 3,500 | | |
| — | |
Other receivables | |
| 2,227 | | |
| 188 | |
Prepaid expenses and other current assets | |
| 1,201 | | |
| 424 | |
Total current assets | |
| 44,038 | | |
| 53,099 | |
Property and equipment, net | |
| 4,489 | | |
| 5,741 | |
Right-of-use lease assets | |
| 4,915 | | |
| 5,331 | |
Other assets | |
| 108 | | |
| 43 | |
Total assets | |
$ | 53,550 | | |
$ | 64,214 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 3,477 | | |
$ | 1,811 | |
Accrued expenses | |
| 4,161 | | |
| 3,991 | |
Current portion of lease liability | |
| 1,597 | | |
| 1,773 | |
Other current liabilities | |
| 205 | | |
| 204 | |
Total current liabilities | |
| 9,440 | | |
| 7,779 | |
Payable to licensor | |
| 4,367 | | |
| 4,163 | |
Long-term lease liabilities | |
| 4,377 | | |
| 5,854 | |
Warrant liabilities | |
| 26,021 | | |
| 19,657 | |
Total liabilities | |
| 44,205 | | |
| 37,453 | |
Commitments and contingencies | |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Common stock - $0.01 par value; authorized 200,000,000 shares; 21,478,157 and 17,719,720 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | |
| 215 | | |
| 177 | |
Additional paid-in capital | |
| 730,322 | | |
| 722,049 | |
Accumulated deficit | |
| (721,097 | ) | |
| (695,336 | ) |
Accumulated other comprehensive loss | |
| (95 | ) | |
| (129 | ) |
Total stockholders’ equity | |
| 9,345 | | |
| 26,761 | |
Total liabilities and stockholders’ equity | |
$ | 53,550 | | |
$ | 64,214 | |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Abeona Therapeutics (NASDAQ:ABEO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Abeona Therapeutics (NASDAQ:ABEO)
Storico
Da Mag 2023 a Mag 2024